Feasibility of 1 hour infliximab infusions.
van Vollenhoven
R F
RF
Gullström
E
E
Klareskog
L
L
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab